Premium
Temozolomide in pediatric low‐grade glioma
Author(s) -
Khaw Seong L.,
Coleman Lee T.,
Downie Peter A.,
Heath John A.,
Ashley David M.
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21270
Subject(s) - temozolomide , medicine , glioma , tolerability , carboplatin , nausea , vincristine , adverse effect , chemotherapy , surgery , dacarbazine , oncology , cisplatin , cyclophosphamide , cancer research
Abstract Background We describe a retrospective series of children with low‐grade glioma who received temozolomide. Procedure Eligible patients had had a diagnosis of low‐grade glioma with or without histological confirmation. Temozolomide was administered at a dose of 200 mg/m 2 daily for 5 days, in a 4‐week cycle. Therapy was stopped on completion of the targeted 12 cycles of chemotherapy or on evidence of tumor progression. Results Thirteen eligible patients were identified, eight male and five female. Median age at diagnosis was 5.5 years (range 2.6–15.0 years) and at commencement of temozolomide treatment was 9.0 years (range 3.8–15.2 years). Nine patients had a histological diagnosis of pilocytic astrocytoma. Twelve patients had received carboplatin prior to temozolomide, including three in combination with vincristine. A total of 111 cycles of therapy have been administered. Hematological toxicity and nausea were the most common adverse effects. Median time to progression was 6.7 months (range 1.5–41.8 months). Event‐free survival rate at 3 years was 57%. Twelve of 13 patients remain alive at the time of report. Eleven have stable disease (SD). Conclusion Temozolomide appears to be active in pediatric low‐grade glioma, with the advantage of oral administration and excellent tolerability. Pediatr Blood Cancer 2007;49:808–811. © 2007 Wiley‐Liss, Inc.